<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314936</url>
  </required_header>
  <id_info>
    <org_study_id>01-2014</org_study_id>
    <nct_id>NCT02314936</nct_id>
  </id_info>
  <brief_title>Dose-ranging Efficacy of Polydextrose Supplement on Colonic Transit Time and Symptoms in Adults With Functional Constipation</brief_title>
  <official_title>Dose-ranging Efficacy of Supplementation With Polydextrose, a Dietary Fibre, on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Science Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DuPont Nutrition and Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Science Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effectiveness of Polydextrose, a dietary fiber, at decreasing
      Colonic Transit Time and the gastrointestinal symptoms of Functional Constipation. One
      quarter of the subjects will receive 12 g of Polydextrose daily, one quarter will receive 8 g
      of Polydextrose daily, one quarter will receive 4 g of Polydextrose daily and one quarter
      will receive a placebo daily.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Colonic Transit Time From Baseline to Day 15</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Assessed using abdominal x-ray. Subjects will take 24 radiopaque markers for 6 consecutive days (144 radiopaque markers in total) immediately preceding the x-ray dates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Participant Assessment of Constipation Symptoms (PAC-SYM) From Baseline to Day 15</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Assessed using the PAC-SYM questionnaire (overall score, abdominal symptoms score, rectal symptoms score, and stool symptoms score).
The PAC-SYM was developed as a brief, easily administered tool to assess symptom frequency and severity of chronic constipation. The authors used a definition for constipation was based on the Rome II criteria. This 12-item self-report measure is divided into the 3 symptom subscales of: abdominal, rectal and stool subscales.
All items (sub-scores and the total score) are scored on a five-point Likert scale ranging from 0 (absence of symptom) to 4 (very severe) where lower scores are better. Scores for the total number of non-missing items within the subscale or total score are summed and divided by the total number of non-missing items for that subscale or total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Participant Assessment of Constipation Quality of Life (PAC-QoL) From Baseline to Day 15</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Assessed using the PAC-QoL questionnaire (Overall Score, Worries and Concerns Score, Physical Discomfort Score, Psychosocial Discomfort Score, and Satisfaction Score)
The Patient Assessment of Constipation (PAC) was developed to address the need for a disease-specific patient-reported outcomes measure. It includes components from complementary symptom and quality of life questionnaires.
The PAC-QOL contains 28 items grouped into 4 subscales covering: worries and concerns (11 items), physical discomfort (4 items), psychosocial discomfort (8 items), and satisfaction (5 items).
A 5-point Likert response scale, ranging from 0 (not at all / none of the time) to 4 (extremely / all of the time), where lower scores are better. Scores are computed as the average non-missing item response within the subscale where each score is given equal weight; the global score is calculated as the mean of the 28-items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bowel Function Index From Baseline to Day 15</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Assessed using the Bowel Function Index questionnaire (total score, ease of defecation, feeling of incomplete bowel evacuation, and personal judgement of constipation).
Each of the three questions used a numerical analog scale (0 = easy/no difficulty/not at all, 100 = very strong/very difficult) for grading purposes. The three questions were calculated as single scores as well as by a total score defined as the average of the three questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Adequate Relief of Constipation Symptoms From Baseline to Day 15</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Assessed using single question dichotomous tool.
Adequate relief quantified the difference in the number of participants experiencing relief from constipation between participants supplemented with Litesse and those supplemented with a placebo at baseline and day 14. The units of analysis for the relief questionnaire were the number of participants who reported relief from constipation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stool Frequency From Baseline to Day 15</measure>
    <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
    <description>Participants will record the number of defecations per day in a daily diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stool Consistency From Baseline to Day 15</measure>
    <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
    <description>Stool consistency will be rated each day in a diary by using the Bristol Stool Scale Form.
Bristol Stool Scale:
The BSS is a categorical scale ranging from 1 to 7 that interprets the consistency of a single bowel movement; a single score is recorded and used for analysis. Lower scores are associated with hard and lumpy consistencies while higher scores are associated with soft or liquid consistencies. Generally, an optimal BSS scores ranges from 3 to 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Degree of Straining During Defecation From Baseline to Day 15</measure>
    <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
    <description>Degree of straining for each bowel movement will be recorded in a daily diary using a 5-point scale.
The degree of straining is a rating scale ranging from 1 (not at al) to 5 (an extreme amount) that interprets the degree to which an individual must strain during a unique defecation; a single core is recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of straining (1-5) where a lower score represented less straining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Sensation of Complete Bowel Emptying From Baseline to Day 15</measure>
    <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
    <description>Sensation of complete bowel emptying for each bowel movement will be recorded in a daily diary on a dichotomous &quot;yes&quot; or &quot;no&quot; scale.
The change in the sensation was defined as the change from baseline to week 2 in the percentage of complete bowel movements (CBMs) between participants supplemented with Litesse and those supplemented with a placebo. It assessed whether the participant felt as though their bowel movement was complete. The units of analysis for the sensation of complete bowel emptying was the weekly percentage of complete bowel movements, for each participant at run-in (week -1), week 1 and week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Severity of Abdominal Discomfort From Baseline to Day 15</measure>
    <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
    <description>Severity of abdominal discomfort will be recorded each day in a daily diary on a 5-point scale.
The severity of abdominal discomfort was calculated from a rating scale ranging from 1 (not at all) to 5 very severe); a single score was recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of discomfort where a lower score represented less straining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Bloating Severity From Baseline to Day 15</measure>
    <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
    <description>Severity of bloating will be recorded each day in a daily diary on a 5-point scale.
The severity of abdominal bloating was calculated from a rating scale ranging from 1 (not at all) to 5 very severe); a single score was recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of bloating where a lower score represented less straining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Product Satisfaction</measure>
    <time_frame>Assessed at Day 15 (end of study)</time_frame>
    <description>Participants will be asked to rate their overall satisfaction with the study product's ability to relieve their constipation symptoms on a 5-point ordinal scale.
The overall product satisfaction questionnaire consists of a single question that provides insight regarding the participants satisfaction on the product's ability to relieve constipation symptoms. The score that the participant indicates is considered the total score and no sub-scores are calculated. It is a rating scale that ranges from 1 (not at all satisfied) to 5 (very satisfied) where a higher score at the end-of-study indicates an improvement.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Hemoglobin Levels From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically hemoglobin in this outcome).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hematocrit Levels From Screening to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring the change in whole blood hematology (specifically hematocrit levels in this outcome).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in White Blood Cell Count From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically white blood cell count in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Red Blood Cell Count From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically red blood cell count in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Mean Corpuscular Volume From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically mean corpuscular volume in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Mean Corpuscular Hemoglobin From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically mean corpuscular hemoglobin in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Mean Corpuscular Hemoglobin Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically mean corpuscular hemoglobin concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Red Cell Distribution Width From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically red cell distribution width in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Platelet Count From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically platelet count in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Neutrophil Count From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically neutrophil count in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Lymphocyte Count From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically lymphocyte count in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Monocyte Count From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically monocyte count in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Eosinophil Count From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically eosinophil count in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Basophil Count From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring whole blood hematology (specifically basophil count in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Glucose Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically glucose concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Creatinine Levels in Blood From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically creatinine concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Urea Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically urea concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Estimated Globular Filtration Rate From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically estimated glomerular filtration rate in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Sodium Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically sodium concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Potassium Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically potassium concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Chloride Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically chloride concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Calcium Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically calcium concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Carbon Dioxide Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically carbon dioxide concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Phosphate Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically phosphate concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Bilirubin Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically bilirubin concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Aspartate Transaminase Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically aspartate transaminase concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Alanine Transaminase Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically alanine transaminase concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Alkaline Phosphate Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically alkaline phosphate concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Gamma-Glutamyltransferase Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically gamma-glutamyltransferase concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum C-Reactive Protein Concentration From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring blood serum variables (specifically C-reactive protein concentration in this outcome measure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Specific Gravity Urinalysis Parameter From Screening to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring urine analyses (specifically specific gravity in this outcome measure). The reference range for specific gravity are 1.001 - 1.030 mmol/L, with no alerting or critical values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in pH Urinalysis Parameter From Baseline to Day 15</measure>
    <time_frame>Screening and Day 15 (end of study)</time_frame>
    <description>Safety will be evaluated by measuring urine analyses (specifically urine pH in this outcome measure). Urine pH reference range is between 5.0 - 8.0, with no alerting or critical values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects With Adverse Events</measure>
    <time_frame>14 days run-in and 14 days treatment</time_frame>
    <description>Adverse events were recorded in a daily diary during the 14-day run-in period and the 14-day treatment period. All types of adverse events as well as the total number of all adverse events reported were used in this outcome measure.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Functional Constipation</condition>
  <arm_group>
    <arm_group_label>Litesse powder containing 12 g polydextrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Litesse powder containing 8 g polydextrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Litesse powder containing 4 g polydextrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Litesse powder containing 12 g polydextrose</intervention_name>
    <description>12 g polydextrose</description>
    <arm_group_label>Litesse powder containing 12 g polydextrose</arm_group_label>
    <other_name>Litesse powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Litesse powder containing 8 g polydextrose</intervention_name>
    <description>8 g polydextrose, 4 g maltodextrin</description>
    <arm_group_label>Litesse powder containing 8 g polydextrose</arm_group_label>
    <other_name>Litesse powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Litesse powder containing 4 g polydextrose</intervention_name>
    <description>4 g polydextrose, 8 g maltodextrin</description>
    <arm_group_label>Litesse powder containing 4 g polydextrose</arm_group_label>
    <other_name>Litesse powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>12 g Maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 70 years.

          2. Body mass index between 18.5 and 29.9 kg/m2 (encompasses normal weight and
             overweight).

          3. If female, subject is not of child bearing potential. Defined as females who have had
             a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal
             (natural or surgically with &gt; 1 year since last menstruation).

             OR

             Female subject of childbearing potential must agree to use a medically approved method
             of birth control and have a negative urine pregnancy test result. Acceptable methods
             of birth control include:

             Hormonal contraceptives including oral contraceptives, hormone birth control patch
             (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives
             (Depo-Provera, Lunelle), or hormone implant (Norplant System), Intrauterine devices,
             Double barrier method, Vasectomy of partner (shown successful as per appropriate
             follow-up), Tubal ligation, and Non-heterosexual lifestyle (same sex partner).

          4. Meets the Rome III criteria for functional constipation as follows: (Criteria
             fulfilled for the last 3 months with symptom onset at least 6 months prior to
             diagnosis):

             Must meet 2 or more of the following criteria:

             Straining during at least 25% of defecations, Lumpy or hard stools in at least 25% of
             defecations, Sensation of incomplete evacuation for at least 25% of defecations,
             Sensation of anorectal obstruction/blockage for at least 25% of defecations, Manual
             maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support
             of the pelvic floor)

             Fewer than three defecations per week

             Loose stools are rarely present without the use of laxatives

             Insufficient criteria for irritable bowel syndrome

          5. Ability of the participant (in the investigator's opinion) to comprehend the full
             nature and purpose of the study including possible risks and side effects.

          6. Consent to the study and willing to comply with study product and methods.

          7. Covered by Health Insurance System and / or in compliance with the recommendations of
             National Law in force relating to biomedical research.

        Exclusion Criteria:

          1. Major gastrointestinal complication (e.g. Crohn's disease, colitis, celiac disease)

          2. Prior abdominal surgery that in the opinion of the investigator may present a risk for
             the subject or confound study results.

          3. Clinically significant underlying systemic illness that may preclude the participant's
             ability to complete the trial or that may confound the study outcomes (e.g. bowel
             cancer, prostate cancer, terminal illness).

          4. Daily consumption of probiotics, prebiotics, fermented milk, and/or yogurt within 2
             weeks of screening and throughout the trial other than the provided study products.

          5. Laxative use within 48 hours of screening (rescue medication allowed for intolerable
             symptoms during study).

          6. Regular use of any drug or dietary supplement known to cause constipation (e.g. iron,
             opioids, sucralfate, misoprostol, 5-HT#-antagonists, antacids with magnesium, calcium
             or aluminum, antidiarrheal medication, anticholinergic agents, calcium supplements,
             calcium channel blockers, tricyclic antidepressants or NSAIDs), within 1 month before
             screening.

          7. Anticipated major dietary or exercise changes during the study.

          8. Systemic steroid use, within 1 month before screening.

          9. Eating disorder.

         10. Contraindication to dairy products (e.g., intolerance to lactose or any substance in
             the study product).

         11. History of alcohol, drug, or medication abuse.

         12. Pregnant or lactating female, or pregnancy planned during study period.

         13. Participation in another study with any investigational product within 60 days of
             screening.

         14. Investigator believes that the participant may be uncooperative and/or noncompliant
             and should therefore not participate in the study.

         15. Subject under administrative or legal supervision.

         16. Subject who would receive more than 4500 Euros as indemnities for his participation in
             biomedical research within the 12 last months, including the indemnities for the
             present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Science Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <results_first_submitted>April 6, 2017</results_first_submitted>
  <results_first_submitted_qc>April 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2018</results_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Constipation</keyword>
  <keyword>Polydextrose</keyword>
  <keyword>Dietary Fiber</keyword>
  <keyword>PAC-QoL</keyword>
  <keyword>Colonic Transit Time</keyword>
  <keyword>PAC-SYM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Litesse Powder Containing 12 g Polydextrose</title>
          <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
        </group>
        <group group_id="P2">
          <title>Litesse Powder Containing 8 g Polydextrose</title>
          <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
        </group>
        <group group_id="P3">
          <title>Litesse Powder Containing 4 g Polydextrose</title>
          <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Litesse Powder Containing 12 g Polydextrose</title>
          <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
        </group>
        <group group_id="B2">
          <title>Litesse Powder Containing 8 g Polydextrose</title>
          <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
        </group>
        <group group_id="B3">
          <title>Litesse Powder Containing 4 g Polydextrose</title>
          <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="48"/>
            <count group_id="B4" value="48"/>
            <count group_id="B5" value="192"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="16.3"/>
                    <measurement group_id="B2" value="42.9" spread="12.5"/>
                    <measurement group_id="B3" value="41.5" spread="17.1"/>
                    <measurement group_id="B4" value="43.6" spread="13.4"/>
                    <measurement group_id="B5" value="42.7" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eastern European White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle Eastern</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North American Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Western European White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.27" spread="3.06"/>
                    <measurement group_id="B2" value="25.31" spread="3.09"/>
                    <measurement group_id="B3" value="25.32" spread="2.82"/>
                    <measurement group_id="B4" value="25.23" spread="2.48"/>
                    <measurement group_id="B5" value="25.28" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Ex-Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Current Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Daily</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occasionally</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weekly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Colonic Transit Time From Baseline to Day 15</title>
        <description>Assessed using abdominal x-ray. Subjects will take 24 radiopaque markers for 6 consecutive days (144 radiopaque markers in total) immediately preceding the x-ray dates.</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Colonic Transit Time From Baseline to Day 15</title>
          <description>Assessed using abdominal x-ray. Subjects will take 24 radiopaque markers for 6 consecutive days (144 radiopaque markers in total) immediately preceding the x-ray dates.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="23.6"/>
                    <measurement group_id="O2" value="4.0" spread="23.4"/>
                    <measurement group_id="O3" value="2.5" spread="23.7"/>
                    <measurement group_id="O4" value="2.6" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Participant Assessment of Constipation Symptoms (PAC-SYM) From Baseline to Day 15</title>
        <description>Assessed using the PAC-SYM questionnaire (overall score, abdominal symptoms score, rectal symptoms score, and stool symptoms score).
The PAC-SYM was developed as a brief, easily administered tool to assess symptom frequency and severity of chronic constipation. The authors used a definition for constipation was based on the Rome II criteria. This 12-item self-report measure is divided into the 3 symptom subscales of: abdominal, rectal and stool subscales.
All items (sub-scores and the total score) are scored on a five-point Likert scale ranging from 0 (absence of symptom) to 4 (very severe) where lower scores are better. Scores for the total number of non-missing items within the subscale or total score are summed and divided by the total number of non-missing items for that subscale or total score.</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Participant Assessment of Constipation Symptoms (PAC-SYM) From Baseline to Day 15</title>
          <description>Assessed using the PAC-SYM questionnaire (overall score, abdominal symptoms score, rectal symptoms score, and stool symptoms score).
The PAC-SYM was developed as a brief, easily administered tool to assess symptom frequency and severity of chronic constipation. The authors used a definition for constipation was based on the Rome II criteria. This 12-item self-report measure is divided into the 3 symptom subscales of: abdominal, rectal and stool subscales.
All items (sub-scores and the total score) are scored on a five-point Likert scale ranging from 0 (absence of symptom) to 4 (very severe) where lower scores are better. Scores for the total number of non-missing items within the subscale or total score are summed and divided by the total number of non-missing items for that subscale or total score.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.59"/>
                    <measurement group_id="O2" value="-0.13" spread="0.39"/>
                    <measurement group_id="O3" value="-0.04" spread="0.44"/>
                    <measurement group_id="O4" value="-0.21" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Symptoms Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.69"/>
                    <measurement group_id="O2" value="-0.06" spread="0.51"/>
                    <measurement group_id="O3" value="-0.01" spread="0.56"/>
                    <measurement group_id="O4" value="-0.15" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal Symptoms Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.71"/>
                    <measurement group_id="O2" value="-0.16" spread="0.46"/>
                    <measurement group_id="O3" value="0.06" spread="0.60"/>
                    <measurement group_id="O4" value="-0.21" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stool Symptoms Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.82"/>
                    <measurement group_id="O2" value="-0.16" spread="0.68"/>
                    <measurement group_id="O3" value="-0.18" spread="0.62"/>
                    <measurement group_id="O4" value="-0.28" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Participant Assessment of Constipation Quality of Life (PAC-QoL) From Baseline to Day 15</title>
        <description>Assessed using the PAC-QoL questionnaire (Overall Score, Worries and Concerns Score, Physical Discomfort Score, Psychosocial Discomfort Score, and Satisfaction Score)
The Patient Assessment of Constipation (PAC) was developed to address the need for a disease-specific patient-reported outcomes measure. It includes components from complementary symptom and quality of life questionnaires.
The PAC-QOL contains 28 items grouped into 4 subscales covering: worries and concerns (11 items), physical discomfort (4 items), psychosocial discomfort (8 items), and satisfaction (5 items).
A 5-point Likert response scale, ranging from 0 (not at all / none of the time) to 4 (extremely / all of the time), where lower scores are better. Scores are computed as the average non-missing item response within the subscale where each score is given equal weight; the global score is calculated as the mean of the 28-items.</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Participant Assessment of Constipation Quality of Life (PAC-QoL) From Baseline to Day 15</title>
          <description>Assessed using the PAC-QoL questionnaire (Overall Score, Worries and Concerns Score, Physical Discomfort Score, Psychosocial Discomfort Score, and Satisfaction Score)
The Patient Assessment of Constipation (PAC) was developed to address the need for a disease-specific patient-reported outcomes measure. It includes components from complementary symptom and quality of life questionnaires.
The PAC-QOL contains 28 items grouped into 4 subscales covering: worries and concerns (11 items), physical discomfort (4 items), psychosocial discomfort (8 items), and satisfaction (5 items).
A 5-point Likert response scale, ranging from 0 (not at all / none of the time) to 4 (extremely / all of the time), where lower scores are better. Scores are computed as the average non-missing item response within the subscale where each score is given equal weight; the global score is calculated as the mean of the 28-items.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.36"/>
                    <measurement group_id="O2" value="-0.04" spread="0.45"/>
                    <measurement group_id="O3" value="-0.08" spread="0.33"/>
                    <measurement group_id="O4" value="-0.11" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worries and Concerns Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.59"/>
                    <measurement group_id="O2" value="-0.17" spread="0.54"/>
                    <measurement group_id="O3" value="-0.15" spread="0.46"/>
                    <measurement group_id="O4" value="-0.13" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Discomfort Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.74"/>
                    <measurement group_id="O2" value="-0.23" spread="0.73"/>
                    <measurement group_id="O3" value="-0.13" spread="0.58"/>
                    <measurement group_id="O4" value="-0.20" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosocial Discomfort Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.53"/>
                    <measurement group_id="O2" value="-0.11" spread="0.58"/>
                    <measurement group_id="O3" value="-0.17" spread="0.52"/>
                    <measurement group_id="O4" value="-0.09" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.98"/>
                    <measurement group_id="O2" value="0.37" spread="0.75"/>
                    <measurement group_id="O3" value="0.12" spread="0.67"/>
                    <measurement group_id="O4" value="-0.02" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bowel Function Index From Baseline to Day 15</title>
        <description>Assessed using the Bowel Function Index questionnaire (total score, ease of defecation, feeling of incomplete bowel evacuation, and personal judgement of constipation).
Each of the three questions used a numerical analog scale (0 = easy/no difficulty/not at all, 100 = very strong/very difficult) for grading purposes. The three questions were calculated as single scores as well as by a total score defined as the average of the three questions.</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bowel Function Index From Baseline to Day 15</title>
          <description>Assessed using the Bowel Function Index questionnaire (total score, ease of defecation, feeling of incomplete bowel evacuation, and personal judgement of constipation).
Each of the three questions used a numerical analog scale (0 = easy/no difficulty/not at all, 100 = very strong/very difficult) for grading purposes. The three questions were calculated as single scores as well as by a total score defined as the average of the three questions.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="23.6"/>
                    <measurement group_id="O2" value="-8.2" spread="20.8"/>
                    <measurement group_id="O3" value="-8.9" spread="20.1"/>
                    <measurement group_id="O4" value="-10.2" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of Defecation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="32.8"/>
                    <measurement group_id="O2" value="-6.2" spread="26.1"/>
                    <measurement group_id="O3" value="-5.9" spread="26.2"/>
                    <measurement group_id="O4" value="-8.8" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling of Incomplete Bowel Evacuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="30.1"/>
                    <measurement group_id="O2" value="-10.9" spread="31.5"/>
                    <measurement group_id="O3" value="-15.1" spread="23.3"/>
                    <measurement group_id="O4" value="-9.5" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal Judgement of Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="27.3"/>
                    <measurement group_id="O2" value="-7.5" spread="24.3"/>
                    <measurement group_id="O3" value="-5.7" spread="20.9"/>
                    <measurement group_id="O4" value="-12.4" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Adequate Relief of Constipation Symptoms From Baseline to Day 15</title>
        <description>Assessed using single question dichotomous tool.
Adequate relief quantified the difference in the number of participants experiencing relief from constipation between participants supplemented with Litesse and those supplemented with a placebo at baseline and day 14. The units of analysis for the relief questionnaire were the number of participants who reported relief from constipation.</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Adequate Relief of Constipation Symptoms From Baseline to Day 15</title>
          <description>Assessed using single question dichotomous tool.
Adequate relief quantified the difference in the number of participants experiencing relief from constipation between participants supplemented with Litesse and those supplemented with a placebo at baseline and day 14. The units of analysis for the relief questionnaire were the number of participants who reported relief from constipation.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Relief at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relief at Day 14 End-of-Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stool Frequency From Baseline to Day 15</title>
        <description>Participants will record the number of defecations per day in a daily diary</description>
        <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stool Frequency From Baseline to Day 15</title>
          <description>Participants will record the number of defecations per day in a daily diary</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>Number of Bowel Movements Per Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="3.3"/>
                    <measurement group_id="O2" value="-0.2" spread="3.3"/>
                    <measurement group_id="O3" value="-0.4" spread="2.2"/>
                    <measurement group_id="O4" value="-0.9" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stool Consistency From Baseline to Day 15</title>
        <description>Stool consistency will be rated each day in a diary by using the Bristol Stool Scale Form.
Bristol Stool Scale:
The BSS is a categorical scale ranging from 1 to 7 that interprets the consistency of a single bowel movement; a single score is recorded and used for analysis. Lower scores are associated with hard and lumpy consistencies while higher scores are associated with soft or liquid consistencies. Generally, an optimal BSS scores ranges from 3 to 5.</description>
        <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stool Consistency From Baseline to Day 15</title>
          <description>Stool consistency will be rated each day in a diary by using the Bristol Stool Scale Form.
Bristol Stool Scale:
The BSS is a categorical scale ranging from 1 to 7 that interprets the consistency of a single bowel movement; a single score is recorded and used for analysis. Lower scores are associated with hard and lumpy consistencies while higher scores are associated with soft or liquid consistencies. Generally, an optimal BSS scores ranges from 3 to 5.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.99"/>
                    <measurement group_id="O2" value="-0.11" spread="0.95"/>
                    <measurement group_id="O3" value="0.30" spread="0.99"/>
                    <measurement group_id="O4" value="0.13" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Degree of Straining During Defecation From Baseline to Day 15</title>
        <description>Degree of straining for each bowel movement will be recorded in a daily diary using a 5-point scale.
The degree of straining is a rating scale ranging from 1 (not at al) to 5 (an extreme amount) that interprets the degree to which an individual must strain during a unique defecation; a single core is recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of straining (1-5) where a lower score represented less straining.</description>
        <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Degree of Straining During Defecation From Baseline to Day 15</title>
          <description>Degree of straining for each bowel movement will be recorded in a daily diary using a 5-point scale.
The degree of straining is a rating scale ranging from 1 (not at al) to 5 (an extreme amount) that interprets the degree to which an individual must strain during a unique defecation; a single core is recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of straining (1-5) where a lower score represented less straining.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.82"/>
                    <measurement group_id="O2" value="-0.26" spread="0.87"/>
                    <measurement group_id="O3" value="-0.15" spread="0.81"/>
                    <measurement group_id="O4" value="-0.09" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Sensation of Complete Bowel Emptying From Baseline to Day 15</title>
        <description>Sensation of complete bowel emptying for each bowel movement will be recorded in a daily diary on a dichotomous &quot;yes&quot; or &quot;no&quot; scale.
The change in the sensation was defined as the change from baseline to week 2 in the percentage of complete bowel movements (CBMs) between participants supplemented with Litesse and those supplemented with a placebo. It assessed whether the participant felt as though their bowel movement was complete. The units of analysis for the sensation of complete bowel emptying was the weekly percentage of complete bowel movements, for each participant at run-in (week -1), week 1 and week 2.</description>
        <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Sensation of Complete Bowel Emptying From Baseline to Day 15</title>
          <description>Sensation of complete bowel emptying for each bowel movement will be recorded in a daily diary on a dichotomous &quot;yes&quot; or &quot;no&quot; scale.
The change in the sensation was defined as the change from baseline to week 2 in the percentage of complete bowel movements (CBMs) between participants supplemented with Litesse and those supplemented with a placebo. It assessed whether the participant felt as though their bowel movement was complete. The units of analysis for the sensation of complete bowel emptying was the weekly percentage of complete bowel movements, for each participant at run-in (week -1), week 1 and week 2.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>Percentage of CBMs per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="27.5"/>
                    <measurement group_id="O2" value="10.2" spread="25.1"/>
                    <measurement group_id="O3" value="7.3" spread="31.3"/>
                    <measurement group_id="O4" value="-3.4" spread="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Severity of Abdominal Discomfort From Baseline to Day 15</title>
        <description>Severity of abdominal discomfort will be recorded each day in a daily diary on a 5-point scale.
The severity of abdominal discomfort was calculated from a rating scale ranging from 1 (not at all) to 5 very severe); a single score was recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of discomfort where a lower score represented less straining.</description>
        <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Severity of Abdominal Discomfort From Baseline to Day 15</title>
          <description>Severity of abdominal discomfort will be recorded each day in a daily diary on a 5-point scale.
The severity of abdominal discomfort was calculated from a rating scale ranging from 1 (not at all) to 5 very severe); a single score was recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of discomfort where a lower score represented less straining.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.57"/>
                    <measurement group_id="O2" value="-0.05" spread="0.61"/>
                    <measurement group_id="O3" value="-0.10" spread="0.58"/>
                    <measurement group_id="O4" value="-0.01" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Bloating Severity From Baseline to Day 15</title>
        <description>Severity of bloating will be recorded each day in a daily diary on a 5-point scale.
The severity of abdominal bloating was calculated from a rating scale ranging from 1 (not at all) to 5 very severe); a single score was recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of bloating where a lower score represented less straining.</description>
        <time_frame>14 day run-in and Week 2 of the 14-day supplementation period</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Bloating Severity From Baseline to Day 15</title>
          <description>Severity of bloating will be recorded each day in a daily diary on a 5-point scale.
The severity of abdominal bloating was calculated from a rating scale ranging from 1 (not at all) to 5 very severe); a single score was recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of bloating where a lower score represented less straining.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.58"/>
                    <measurement group_id="O2" value="-0.23" spread="0.47"/>
                    <measurement group_id="O3" value="-0.12" spread="0.49"/>
                    <measurement group_id="O4" value="-0.03" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Product Satisfaction</title>
        <description>Participants will be asked to rate their overall satisfaction with the study product's ability to relieve their constipation symptoms on a 5-point ordinal scale.
The overall product satisfaction questionnaire consists of a single question that provides insight regarding the participants satisfaction on the product's ability to relieve constipation symptoms. The score that the participant indicates is considered the total score and no sub-scores are calculated. It is a rating scale that ranges from 1 (not at all satisfied) to 5 (very satisfied) where a higher score at the end-of-study indicates an improvement.</description>
        <time_frame>Assessed at Day 15 (end of study)</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Product Satisfaction</title>
          <description>Participants will be asked to rate their overall satisfaction with the study product's ability to relieve their constipation symptoms on a 5-point ordinal scale.
The overall product satisfaction questionnaire consists of a single question that provides insight regarding the participants satisfaction on the product's ability to relieve constipation symptoms. The score that the participant indicates is considered the total score and no sub-scores are calculated. It is a rating scale that ranges from 1 (not at all satisfied) to 5 (very satisfied) where a higher score at the end-of-study indicates an improvement.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="1.20"/>
                    <measurement group_id="O2" value="3.09" spread="1.23"/>
                    <measurement group_id="O3" value="2.54" spread="1.14"/>
                    <measurement group_id="O4" value="2.62" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hemoglobin Levels From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically hemoglobin in this outcome).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Levels From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically hemoglobin in this outcome).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="5.1"/>
                    <measurement group_id="O2" value="-0.9" spread="5.5"/>
                    <measurement group_id="O3" value="-1.4" spread="5.1"/>
                    <measurement group_id="O4" value="0.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hematocrit Levels From Screening to Day 15</title>
        <description>Safety will be evaluated by measuring the change in whole blood hematology (specifically hematocrit levels in this outcome).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hematocrit Levels From Screening to Day 15</title>
          <description>Safety will be evaluated by measuring the change in whole blood hematology (specifically hematocrit levels in this outcome).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>Percentage of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0045" spread="0.0156"/>
                    <measurement group_id="O2" value="-0.0008" spread="0.0166"/>
                    <measurement group_id="O3" value="-0.0057" spread="0.0141"/>
                    <measurement group_id="O4" value="0.0031" spread="0.0146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in White Blood Cell Count From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically white blood cell count in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in White Blood Cell Count From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically white blood cell count in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="1.56"/>
                    <measurement group_id="O2" value="-0.34" spread="1.19"/>
                    <measurement group_id="O3" value="-0.19" spread="1.24"/>
                    <measurement group_id="O4" value="0.06" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Red Blood Cell Count From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically red blood cell count in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Red Blood Cell Count From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically red blood cell count in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>10^12 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.052" spread="0.157"/>
                    <measurement group_id="O2" value="-0.030" spread="0.171"/>
                    <measurement group_id="O3" value="-0.053" spread="0.163"/>
                    <measurement group_id="O4" value="0.034" spread="0.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Mean Corpuscular Volume From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically mean corpuscular volume in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Corpuscular Volume From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically mean corpuscular volume in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="1.13"/>
                    <measurement group_id="O2" value="0.23" spread="1.09"/>
                    <measurement group_id="O3" value="-0.19" spread="1.21"/>
                    <measurement group_id="O4" value="-0.09" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Mean Corpuscular Hemoglobin From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically mean corpuscular hemoglobin in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Corpuscular Hemoglobin From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically mean corpuscular hemoglobin in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>pg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.75"/>
                    <measurement group_id="O2" value="-0.02" spread="0.63"/>
                    <measurement group_id="O3" value="0.04" spread="0.46"/>
                    <measurement group_id="O4" value="-0.15" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Mean Corpuscular Hemoglobin Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically mean corpuscular hemoglobin concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Corpuscular Hemoglobin Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically mean corpuscular hemoglobin concentration in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="5.2"/>
                    <measurement group_id="O2" value="-0.9" spread="5.9"/>
                    <measurement group_id="O3" value="1.4" spread="4.7"/>
                    <measurement group_id="O4" value="-1.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Red Cell Distribution Width From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically red cell distribution width in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Red Cell Distribution Width From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically red cell distribution width in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>percent of mean red blood cell volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.35"/>
                    <measurement group_id="O2" value="0.06" spread="0.33"/>
                    <measurement group_id="O3" value="-0.03" spread="0.62"/>
                    <measurement group_id="O4" value="-0.08" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Platelet Count From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically platelet count in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Platelet Count From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically platelet count in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="20.4"/>
                    <measurement group_id="O2" value="6.0" spread="27.0"/>
                    <measurement group_id="O3" value="-5.9" spread="25.9"/>
                    <measurement group_id="O4" value="1.6" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Neutrophil Count From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically neutrophil count in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Neutrophil Count From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically neutrophil count in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="1.43"/>
                    <measurement group_id="O2" value="-0.19" spread="1.00"/>
                    <measurement group_id="O3" value="-0.19" spread="1.00"/>
                    <measurement group_id="O4" value="0.10" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Lymphocyte Count From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically lymphocyte count in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lymphocyte Count From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically lymphocyte count in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.44"/>
                    <measurement group_id="O2" value="-0.10" spread="0.36"/>
                    <measurement group_id="O3" value="-0.01" spread="0.39"/>
                    <measurement group_id="O4" value="-0.06" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Monocyte Count From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically monocyte count in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Monocyte Count From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically monocyte count in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.39"/>
                    <measurement group_id="O2" value="-0.012" spread="0.13"/>
                    <measurement group_id="O3" value="-0.006" spread="0.139"/>
                    <measurement group_id="O4" value="0.021" spread="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Eosinophil Count From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically eosinophil count in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Eosinophil Count From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically eosinophil count in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.090"/>
                    <measurement group_id="O2" value="-0.025" spread="0.076"/>
                    <measurement group_id="O3" value="0.030" spread="0.197"/>
                    <measurement group_id="O4" value="0.029" spread="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Basophil Count From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring whole blood hematology (specifically basophil count in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Basophil Count From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring whole blood hematology (specifically basophil count in this outcome measure).</description>
          <population>Whole blood hematology was not obtained from two participants (one participant in the Litesse powder containing 12 g polydextrose arm and one participant in the Litesse powder containing 4 g polydextrose).</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.042"/>
                    <measurement group_id="O2" value="0.008" spread="0.050"/>
                    <measurement group_id="O3" value="0.002" spread="0.033"/>
                    <measurement group_id="O4" value="0.010" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Glucose Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically glucose concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>The number analyzed from the Litesse powder 4g arm is only 47 due to laboratory analysis error.</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Glucose Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically glucose concentration in this outcome measure).</description>
          <population>The number analyzed from the Litesse powder 4g arm is only 47 due to laboratory analysis error.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.42"/>
                    <measurement group_id="O2" value="0.04" spread="0.46"/>
                    <measurement group_id="O3" value="-0.15" spread="0.44"/>
                    <measurement group_id="O4" value="-0.10" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Creatinine Levels in Blood From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically creatinine concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Creatinine Levels in Blood From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically creatinine concentration in this outcome measure).</description>
          <units>mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="8.4"/>
                    <measurement group_id="O2" value="-0.1" spread="5.9"/>
                    <measurement group_id="O3" value="0.6" spread="4.8"/>
                    <measurement group_id="O4" value="0.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Urea Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically urea concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urea Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically urea concentration in this outcome measure).</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="1.11"/>
                    <measurement group_id="O2" value="-0.31" spread="1.00"/>
                    <measurement group_id="O3" value="-0.10" spread="1.03"/>
                    <measurement group_id="O4" value="0.08" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Estimated Globular Filtration Rate From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically estimated glomerular filtration rate in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Estimated Globular Filtration Rate From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically estimated glomerular filtration rate in this outcome measure).</description>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="10.8"/>
                    <measurement group_id="O2" value="1.4" spread="7.8"/>
                    <measurement group_id="O3" value="-0.1" spread="5.6"/>
                    <measurement group_id="O4" value="-1.9" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Sodium Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically sodium concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Sodium Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically sodium concentration in this outcome measure).</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="2.94"/>
                    <measurement group_id="O2" value="-0.27" spread="2.30"/>
                    <measurement group_id="O3" value="-0.83" spread="2.60"/>
                    <measurement group_id="O4" value="-0.19" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Potassium Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically potassium concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>One participant in the Litesse powder containing 4 g polydextrose arm did not have this blood serum variable analysed due to laboratory analysis error.</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Potassium Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically potassium concentration in this outcome measure).</description>
          <population>One participant in the Litesse powder containing 4 g polydextrose arm did not have this blood serum variable analysed due to laboratory analysis error.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.53"/>
                    <measurement group_id="O2" value="-0.01" spread="0.61"/>
                    <measurement group_id="O3" value="-0.21" spread="0.50"/>
                    <measurement group_id="O4" value="-0.01" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Chloride Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically chloride concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Chloride Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically chloride concentration in this outcome measure).</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="2.32"/>
                    <measurement group_id="O2" value="-0.004" spread="2.40"/>
                    <measurement group_id="O3" value="-0.71" spread="2.08"/>
                    <measurement group_id="O4" value="-0.29" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Calcium Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically calcium concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Calcium Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically calcium concentration in this outcome measure).</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.101"/>
                    <measurement group_id="O2" value="0.016" spread="0.092"/>
                    <measurement group_id="O3" value="-0.004" spread="0.085"/>
                    <measurement group_id="O4" value="0.028" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Carbon Dioxide Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically carbon dioxide concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>One participant in the Litesse powder containing 4 g polydextrose arm did not have this blood serum variable analysed due to laboratory analysis error.</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Carbon Dioxide Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically carbon dioxide concentration in this outcome measure).</description>
          <population>One participant in the Litesse powder containing 4 g polydextrose arm did not have this blood serum variable analysed due to laboratory analysis error.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="2.73"/>
                    <measurement group_id="O2" value="0.31" spread="2.49"/>
                    <measurement group_id="O3" value="-0.13" spread="2.65"/>
                    <measurement group_id="O4" value="-0.50" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Phosphate Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically phosphate concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Phosphate Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically phosphate concentration in this outcome measure).</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="0.147"/>
                    <measurement group_id="O2" value="-0.034" spread="0.165"/>
                    <measurement group_id="O3" value="0.012" spread="0.168"/>
                    <measurement group_id="O4" value="-0.003" spread="0.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Bilirubin Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically bilirubin concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Bilirubin Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically bilirubin concentration in this outcome measure).</description>
          <units>mol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="4.0"/>
                    <measurement group_id="O2" value="0.6" spread="3.3"/>
                    <measurement group_id="O3" value="0.1" spread="3.4"/>
                    <measurement group_id="O4" value="0.6" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Aspartate Transaminase Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically aspartate transaminase concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Aspartate Transaminase Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically aspartate transaminase concentration in this outcome measure).</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="4.5"/>
                    <measurement group_id="O2" value="3.2" spread="16.2"/>
                    <measurement group_id="O3" value="-0.1" spread="7.8"/>
                    <measurement group_id="O4" value="0.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Alanine Transaminase Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically alanine transaminase concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Alanine Transaminase Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically alanine transaminase concentration in this outcome measure).</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="7.0"/>
                    <measurement group_id="O2" value="-0.1" spread="7.7"/>
                    <measurement group_id="O3" value="-1.0" spread="9.5"/>
                    <measurement group_id="O4" value="-0.6" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Alkaline Phosphate Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically alkaline phosphate concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Alkaline Phosphate Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically alkaline phosphate concentration in this outcome measure).</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="6.7"/>
                    <measurement group_id="O2" value="-0.7" spread="7.7"/>
                    <measurement group_id="O3" value="-1.0" spread="7.0"/>
                    <measurement group_id="O4" value="1.9" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Gamma-Glutamyltransferase Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically gamma-glutamyltransferase concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Gamma-Glutamyltransferase Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically gamma-glutamyltransferase concentration in this outcome measure).</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="4.0"/>
                    <measurement group_id="O2" value="-1.6" spread="6.1"/>
                    <measurement group_id="O3" value="0.3" spread="6.2"/>
                    <measurement group_id="O4" value="-2.8" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum C-Reactive Protein Concentration From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring blood serum variables (specifically C-reactive protein concentration in this outcome measure).</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum C-Reactive Protein Concentration From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring blood serum variables (specifically C-reactive protein concentration in this outcome measure).</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.6"/>
                    <measurement group_id="O2" value="0.1" spread="4.4"/>
                    <measurement group_id="O3" value="-0.2" spread="2.4"/>
                    <measurement group_id="O4" value="0.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Specific Gravity Urinalysis Parameter From Screening to Day 15</title>
        <description>Safety will be evaluated by measuring urine analyses (specifically specific gravity in this outcome measure). The reference range for specific gravity are 1.001 - 1.030 mmol/L, with no alerting or critical values.</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>One participant from the 12 g polydextrose arm, one participant from the 8 g polydextrose arm, and three participants from the 4 g polydextrose arm were unable to have urinalysis parameters analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Specific Gravity Urinalysis Parameter From Screening to Day 15</title>
          <description>Safety will be evaluated by measuring urine analyses (specifically specific gravity in this outcome measure). The reference range for specific gravity are 1.001 - 1.030 mmol/L, with no alerting or critical values.</description>
          <population>One participant from the 12 g polydextrose arm, one participant from the 8 g polydextrose arm, and three participants from the 4 g polydextrose arm were unable to have urinalysis parameters analysed.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0010" spread="0.0072"/>
                    <measurement group_id="O2" value="0.0007" spread="0.0071"/>
                    <measurement group_id="O3" value="0.0005" spread="0.0135"/>
                    <measurement group_id="O4" value="0.0029" spread="0.0096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in pH Urinalysis Parameter From Baseline to Day 15</title>
        <description>Safety will be evaluated by measuring urine analyses (specifically urine pH in this outcome measure). Urine pH reference range is between 5.0 - 8.0, with no alerting or critical values.</description>
        <time_frame>Screening and Day 15 (end of study)</time_frame>
        <population>One participant from the 12 g polydextrose arm, one participant from the 8 g polydextrose arm, and three participants from the 4 g polydextrose arm were unable to have urinalysis parameters analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in pH Urinalysis Parameter From Baseline to Day 15</title>
          <description>Safety will be evaluated by measuring urine analyses (specifically urine pH in this outcome measure). Urine pH reference range is between 5.0 - 8.0, with no alerting or critical values.</description>
          <population>One participant from the 12 g polydextrose arm, one participant from the 8 g polydextrose arm, and three participants from the 4 g polydextrose arm were unable to have urinalysis parameters analysed.</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.97"/>
                    <measurement group_id="O2" value="0.20" spread="1.10"/>
                    <measurement group_id="O3" value="0.02" spread="1.02"/>
                    <measurement group_id="O4" value="0.06" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects With Adverse Events</title>
        <description>Adverse events were recorded in a daily diary during the 14-day run-in period and the 14-day treatment period. All types of adverse events as well as the total number of all adverse events reported were used in this outcome measure.</description>
        <time_frame>14 days run-in and 14 days treatment</time_frame>
        <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Litesse Powder Containing 12 g Polydextrose</title>
            <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
          </group>
          <group group_id="O2">
            <title>Litesse Powder Containing 8 g Polydextrose</title>
            <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
          </group>
          <group group_id="O3">
            <title>Litesse Powder Containing 4 g Polydextrose</title>
            <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events</title>
          <description>Adverse events were recorded in a daily diary during the 14-day run-in period and the 14-day treatment period. All types of adverse events as well as the total number of all adverse events reported were used in this outcome measure.</description>
          <population>The number of participants analysed is the number of participants who met the per protocol population requirement. 17 participants did not meet the per protocol compliance (must have consumed 80% of assigned study product and 100% of radio opaque pellets) and 2 participants did not complete the study (did not complete end-of-study visit).</population>
          <units>Number of Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported between Day -14 to Day 14 (run-in and intervention periods).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Litesse Powder Containing 12 g Polydextrose</title>
          <description>12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 12 g polydextrose: 12 g polydextrose</description>
        </group>
        <group group_id="E2">
          <title>Litesse Powder Containing 8 g Polydextrose</title>
          <description>8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 8 g polydextrose: 8 g polydextrose, 4 g maltodextrin</description>
        </group>
        <group group_id="E3">
          <title>Litesse Powder Containing 4 g Polydextrose</title>
          <description>4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Litesse powder containing 4 g polydextrose: 4 g polydextrose, 8 g maltodextrin</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Placebo: 12 g Maltodextrin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Frequent Bowel Movements</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study population was not sufficiently constipated at baseline.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Tetyana Pelipyagina</name_or_title>
      <organization>KGK Synergize Inc.</organization>
      <phone>5194389374</phone>
      <email>drtetyana@kgksynergize.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

